Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
Phase of Trial: Phase 0
Latest Information Update: 14 Jul 2017
Price : $35 *
At a glance
- Drugs PGN 650 I-124 (Primary)
- Indications Solid tumours
- Focus Diagnostic use
- Sponsors Peregrine Pharmaceuticals
- 03 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 03 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 03 Mar 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.